---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008673"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:55:58.785990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xilio reports Q1 net loss $22.6M; initiates Phase 2 trial for XTX202

## Summary
- Cash and cash equivalents $93.3M as of Mar 31, 2023; runway into Q2 2024.
- Phase 2 trial started for XTX202 (tumor-activated IL-2) in advanced RCC and melanoma.
- R&D expenses $16.1M, up from $14.9M, driven by clinical and manufacturing activities.
- Net loss $22.6M vs $21.4M in Q1 2022.
- Plan to report preliminary Phase 1 data for XTX101 (anti-CTLA-4) in Q2 2023.

## SEC filing metadata
- accession: 0001558370-23-008673
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/0001558370-23-008673-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/xlo-20230509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008673
- JSON: https://secwatch.observer/filing/0001558370-23-008673.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008673.txt

## Key facts
- Earnings Releases
  Xilio Therapeutics, Inc. reported first quarter ended March 31, 2023 results: net income $22.6 million.
  - Period: first quarter ended March 31, 2023
  - Net income: $22.6 million
  - Result: reported results
  source text: Xilio Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2023 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023008673/0001558370-23-008673-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.